Inhibrx News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

23.01.24	Sanofi-Aktie gibt nach: Sanofi legt 2,2 Milliarden Dollar für Therapiekandidaten von Inhibrx auf den Tisch (Dow Jones) Sanofi will ein Medikamentenprogramm für eine mögliche Behandlung der Erbkrankheit des Alpha-1-Antitrypsin-Mangels erwerben, durch den Lunge und Leber geschädigt werden.» mehr
23.01.24	Inhibrx To Sell INBRX-101 To Sanofi For Up To $2.2 Bln (RTTNews)
09.11.23	Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (PR Newswire)
02.11.23	Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma (PR Newswire)
18.10.23	Inhibrx Announces Participation in Upcoming Scientific Conferences (PR Newswire)
19.09.23	Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada (PR Newswire)
29.08.23	Inhibrx Announces $200 Million Private Placement Financing (PR Newswire)
07.08.23	Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (PR Newswire)
30.05.23	Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency (PR Newswire)
08.05.23	Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (PR Newswire)
26.04.23	Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials (PR Newswire)
06.03.23	Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results (PR Newswire)
04.01.23	NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates (PR Newswire)
18.11.22	Inhibrx Announces Participation in Upcoming Investor Conference (PR Newswire)
16.11.22	Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma (PR Newswire)
07.11.22	Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights (PR Newswire)
20.10.22	Inhibrx Announces Participation in Upcoming Scientific Conferences (PR Newswire)
04.10.22	Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study (PR Newswire)
03.10.22	Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency (PR Newswire)
15.08.22	European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma (PR Newswire)
08.08.22	Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights (PR Newswire)
30.06.22	Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance (PR Newswire)
19.05.22	Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting (PR Newswire)
16.05.22	INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing (PR Newswire)
09.05.22	Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights (PR Newswire)
25.04.22	Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101 (PR Newswire)
05.04.22	Inhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting (PR Newswire)
24.03.22	Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting (PR Newswire)
03.03.22	Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency (PR Newswire)
28.02.22	Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights (PR Newswire)
22.02.22	Inhibrx Announces Amended Loan Agreement with Oxford (PR Newswire)
04.01.22	Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data (PR Newswire)
01.12.21	Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma (PR Newswire)
09.11.21	Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights (PR Newswire)
03.11.21	Inhibrx Announces Presentations at SITC 2021 (PR Newswire)
01.11.21	Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences (PR Newswire)
28.10.21	Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors (PR Newswire)
12.10.21	INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing (PR Newswire)
11.10.21	Inhibrx To Host Webcast Presentation of Interim Results from the Phase 1 Trial of INBRX-101, its Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency (PR Newswire)
13.09.21	Inhibrx Announces Participation in Upcoming Investor Conference (PR Newswire)
19.08.21	A Sneak Peak Into Inhibrx (RTTNews)
09.08.21	Inhibrx Reports Second Quarter 2021 Financial Results (PR Newswire)
21.06.21	Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement ... (PR Newswire)
17.02.21	BLUE Hit By SCD Trial Blues, CRTX Plunges On Partial Hold, SESN To Face FDA In August (RTTNews)
26.01.21	AZN Rejects Media Reports, MRK Quits COVID-19 Vaccine Work, MRNA Sets Eyes On New SARS-CoV-2 Strains (RTTNews)
13.11.20	AZN's Repurposed COVID-19 Drug Fails, NAVB On Watch, CVAC Rallies On Storage Advantage Of CVnCoV (RTTNews)
18.08.20	This Week's Healthcare IPOs (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	49.98	1.01 %	K V
Part Grp Hldg	1’276.00	0.79 %	K V
UBS Group	28.22	0.50 %	K V
Lonza Grp	522.60	0.42 %	K V
Geberit	526.80	0.30 %	K V
Alcon	77.70	-0.44 %	K V
Sika	227.30	-0.44 %	K V
Swisscom	507.00	-0.59 %	K V
Novartis	92.54	-0.90 %	K V
Nestle	75.94	-0.91 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Inhibrx Inc Registered Shs Accred Inv

Aktien Top/Flop

Inhibrx Peer Group Nachrichten

Meistgelesene Nachrichten